CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Shareholder vote results
- 8-K Event Executive or director change
- 144 Insider Sale of Securities
- 8-K Event Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Chief Technical Officer acquired 186,219 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Executive or director change
- 4 Grant or award VP, Corporate Counsel acquired 56,545 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Technical Officer acquired 558,094 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 558,094 shares (grant or award)
- 4 Grant or award EVP of R&D acquired 148,035 shares (grant or award)
- 4 Grant or award Director acquired 1,282,976 shares (grant or award)
- 4 Grant or award President and CEO acquired 1,924,464 shares (grant or award)
- 4 Shares withheld for taxes President and CEO gave up 22,340 shares (to pay taxes)
Page 14 of 30 · 587 filings